Goal-directed fluid removal with furosemide versus placebo in intensive care patients with fluid overload: A randomised, blinded trial (GODIF trial—First version)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 602 KB, PDF-dokument

Background
Salt and water accumulation leading to fluid overload is associated with increased mortality in intensive care unit (ICU) patients, but diuretics' effects on patient outcomes are uncertain. In this first version of the GODIF trial, we aimed to assess the effects of goal-directed fluid removal with furosemide versus placebo in adult ICU patients with fluid overload.

Methods
We conducted a multicentre, randomised, stratified, parallel-group, blinded, placebo-controlled trial in clinically stable, adult ICU patients with at least 5% fluid overload. Participants were randomised to furosemide versus placebo infusion aiming at achieving neutral cumulative fluid balance as soon as possible. The primary outcome was the number of days alive and out of the hospital at 90 days.

Results
The trial was terminated after the enrolment of 41 of 1000 participants because clinicians had difficulties using cumulative fluid balance as the only estimate of fluid status (32% of participants had their initially registered cumulative fluid balance adjusted and 29% experienced one or more protocol violations). The baseline cumulative fluid balance was 6956 ml in the furosemide group and 6036 ml in the placebo group; on day three, the cumulative fluid balances were 1927 ml and 5139 ml. The median number of days alive and out of hospital at day 90 was 50 days in the furosemide group versus 45 days in the placebo group (mean difference 1 day, 95% CI -19 to 21, p-value .94).

Conclusions
The use of cumulative fluid balance as the only estimate of fluid status appeared too difficult to use in clinical practice. We were unable to provide precise estimates for any outcomes as only 4.1% of the planned sample size was randomised
OriginalsprogEngelsk
TidsskriftActa Anaesthesiologica Scandinavica
Vol/bind67
Udgave nummer4
Sider (fra-til)470-478
Antal sider9
ISSN0001-5172
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The trial was funded by grants from the Novo Nordisk Foundation and Jackob Madsen's and wife Olga Madsen's foundation. The funding organisations have not been involved in the design, conduct, analyses, or reporting of the trial or have any ownership of the data.

Funding Information:
We thank all patients, relatives, clinical staff, and research staff at the participating sites, and the funding bodies. Morten H. Bestle has received research funding from the Novo Nordisk Foundation, Sygeforsikringen “danmark”, Jakob Madsen's and his wife Olga Madsen's foundation, and Svend Andersen's foundation. Sine Wichmann received research funding from Merchant Jakob Ehrenreich and his wife Grete Ehrenreich's Foundation. Anders Perner has received research funding from the Novo Nordisk Foundation, Sygeforsikringen “danmark”, and Pfizer, Denmark. Martin Schønemann‐Lund, Theis S. Itenov, Rasmus E. Berthelsen, Christian Gluud, Theis Lange, Anne C. Brøchner, Jørgen Wiis: none known.

Publisher Copyright:
© 2023 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 336447342